Anti-SLC34A2 (Lifastuzumab) -SMCC-DM1
Anti-SLC34A2 (Lifastuzumab) -SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab conjugated to the linker SMCC (HY-42360) and the the cytotoxic microtubule inhibitor DM1 (HY-19792). The ADC toxic molecule and linker part are SMCC-DM1 (HY-101070). Anti-SLC34A2 (Lifastuzumab) -SMCC-DM1 can be used in the research of cancer[1][2].
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin; Sodium Channel
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[Anti-SLC34A2(Lifastuzumab)-SMCC-DM1]
References & Citations
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin, HMW (AE-3), CF740 conjugate, 0.1mg/mL
IgA Secretory Component (SC05), CF488A conjugate, 0.1mg/mL
ACTH (Adrenocorticotrophic Hormone) (AH26), CF740 conjugate, 0.1mg/mL
